Complicated Intra-Abdominal Infections is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Complicated Intra-Abdominal Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Complicated Intra-Abdominal Infections compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Complicated Intra-Abdominal Infections overview

Complicated intra-abdominal infections (cIAIs) are infections that affect the peritoneal cavity or its organs and require surgical intervention or drainage to achieve source control. cIAIs are usually caused by a disruption of the gastrointestinal tract that allows the entry of normal or pathogenic microorganisms into the sterile peritoneal space. cIAIs are associated with high morbidity and mortality, especially in patients with severe illness, delayed diagnosis, inadequate source control, or inappropriate antimicrobial therapy. The management of cIAIs involves a multidisciplinary approach that includes early recognition, prompt hemodynamic resuscitation, effective source control, and rational antimicrobial therapy. The choice of antimicrobial agents should be based on the likely pathogens, the severity of infection, the risk factors for resistant organisms, and the local epidemiology. Empirical therapy should be started as soon as possible and tailored according to the culture results and the clinical response.

For a complete picture of PTSR and LoA scores for drugs in Complicated Intra-Abdominal Infections, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.